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Abstract 
Due to the low frequency of abnormalities affecting the spleen, this organ is often overlooked during 
radiological examinations. Here, we report on the unexpected finding, that the spleen signal on 
diffusion-weighted MRI (DW-MRI) is associated with clinical parameters in patients with plasma cell 
dyscrasias.  
Methods: We investigated the spleen signal on DW-MRI together with clinical and molecular 
parameters in 295 transplant-eligible newly diagnosed Multiple Myeloma (NDMM) patients and in 72 
cases with monoclonal gammopathy of undetermined significance (MGUS). 
Results: Usually, the spleen is the abdominal organ with the highest intensities on DW-MRI. Yet, 
significant signal loss on DW-MRI images was seen in 71 of 295 (24%) NDMM patients. This 
phenomenon was associated with the level of bone marrow plasmacytosis (P=1x10-10) and 
International Staging System 3 (P=0.0001) but not with gain(1q), and del(17p) or plasma cell gene 
signatures. The signal was preserved in 72 individuals with monoclonal gammopathy of 
undetermined significance and generally re-appeared in MM patients responding to treatment, 
suggesting that lack of signal reflects increased tumor burden. While absence of spleen signal in MM 
patients with high risk disease defined a subgroup with very poor outcome, re-appearance of the 
spleen signal after autologous stem cell transplantation was seen in patients with improved 
outcome. Our preliminary observation suggests that extramedullary hematopoiesis in the spleen is 
a factor that modifies the DW-MRI signal of this organ. 
Conclusions: The DW-MRI spleen signal is a promising marker for tumor load and provides 
prognostic information in MM. 











Whole body imaging is an integral component of 
Multiple Myeloma (MM) evaluation as it reveals bone 
disease and tumor infiltration [1]. While established 
techniques, such as 18F-Fluorodeoxyglucose (FDG)- 
positron emission tomography computer tomography 
(PET-CT), are powerful in delineating focal lesions 
(FLs) [2-5], they suffer from low specificity when it 
comes to assessment of diffuse bone marrow (BM) 
signals, which originate from interstitial MM growth. 
Diffusion-weighted MRI with background 
suppression (DW-MRI) is a functional technique, 
which measures water diffusion in vivo [6]. As 
diffusion of water is more restricted in tissues with 
high cellularity, DW-MRI is a promising technique for 
investigating diffuse BM signals. To classify the 
intensity of the BM signal in MM patients using 
DW-MRI, we selected the spleen as internal reference, 
since it is the abdominal organ with the highest 
restriction [7]. Unexpectedly, we observed significant 
heterogeneity in the spleen signal itself including a 
subgroup of MM patients with total lack of spleen 
visualization. Lack of signal was primarily seen in 
patients with hyperintense diffuse BM signals, 
suggesting that the spleen intensity could be a 
candidate surrogate marker for tumor load in MM. 
Here, we report on our attempt to elucidate this 
phenomenon and to evaluate its clinical value. 
Methods 
Patients 
We investigated 295 transplant-eligible newly 
diagnosed MM (NDMM) patients (Table 1) and 72 
cases with monoclonal gammopathy of undetermined 
significance (MGUS). All NDMM patients were 
treated with novel agents and at least one autologous 
stem cell transplantation. Conventional response was 
assessed according to the IMWG criteria [8]. The 
study was performed under University of Arkansas 
for Medical Sciences IRB approval (#205415), and all 
patients signed written consent in accordance with the 
Declaration of Helsinki. 
Functional Imaging 
DW-MRI was performed on a 1.5 Tesla Philips 
Achieva scanner as described previously [9]. Briefly, 
the protocol included scanning from vertex to toes in 
7-9 slabs depending on patient height. Each slab 
constituted 50 slices 5 mm thick, field of view 450 mm, 
matrix 112x79, repetition time 7500 ms, time to echo 
69.9 ms, number of acquisitions 2, with a "Q" body 
coil, b=0 and 800 s/mm2. A coronal whole body T1 
turbo-spin echo image was obtained as a localizer. 
Asplenia was excluded using coronal T1 weighted 
whole body survey images. Next, the spleen signal 
was assessed on inverted greyscale b800 DWI and 
exponential ADC (eADC) maps by two experienced 
investigators in consensus read. Absence of spleen 
signal was defined as (1) significant signal loss on the 
DWI (b800) image with isointensity to fat tissue, and 
(2) lack of spleen visualization on the corresponding 
EADC map. ADC values were not considered for this 
study. 
For anti-CD66 antibody scintigraphy, the murine 
anti-CD66 monoclonal antibody BW 250/183 (anti- 
Granulocyte®, Scintec Diagnostics, Zug, Switzerland) 
was labelled with 99mTc. Planar whole body imaging 
using a dual-head γ-camera (Symbia Intevo, Siemens 
Healthineers, Erlangen, Germany) was performed 4 h 
and 24 h after iv injection of 650-700 MBq of the 
radiolabeled antibody. Low-energy, high-resolution 
collimators were used. A 15% energy window was 
centered over the 140-keV photopeak of 99mTc. After 
the acquisition of the 24h-planar scans, an additional 
SPECT/CT emission/transmission study of the 
abdomen was performed (Symbia Intevo, Siemens 
Healthineers, 180-degree acquisition per detector, 256 
x 256 matrix, 3-degree steps, and 20 s/frame; CT: 110 
kV, 35 mAs). Images were reconstructed using an 
iterative ordered subsets expectation maximization 
algorithm (Flash 3D: 6 subsets, 6 iterations), both with 
and without CT-based attenuation correction. 
 
Table 1. Patients’ characteristics 
Characteristics No. of Patients (%) 
 Total (N=295) 
Age  
> 65 years 107 (36) 
Sex  
Male 182 (62) 
Myeloma type  
IgG 179 (61) 
ISS  
I 77 (26) 
II 140 (47) 
III 78 (26) 
GEP70  
low 258 (87) 
high 37 (13) 
 
 
Molecular analyses and risk stratification 
Molecular characterization included fluor-
escence in-situ hybridization (FISH), and gene 
expression profiling (GEP) of CD138-enriched plasma 
cells (PCs) [10]. Differential gene expression was 
performed using a threshold of 2-fold difference as 
described previously [11]. GEP70-based risk designa-
tion and determination of the ISS were performed as 
described [12, 13]. 






The Kaplan-Meier method was used for survival 
analyses. PFS time was measured from start of 
treatment to relapse or death from any cause or 
censored at the date of last contact. Wilcoxon and 
Fisher’s exact tests were used to compare the median 
of a continuous variable or the distribution of discrete 
variables across groups, respectively. Main analyses 
were undertaken using R (v3.3.1) software. 
Results 
Lack of spleen signal on DW-MRI is associated 
with tumor load 
Lack of spleen signal on DW-MRI was common 
in NDMM, seen in 71/295 (24%) patients. To elucidate 
the underpinnings of this observation, we correlated it 
with various clinical and molecular parameters. Lack 
of signal was highly positively associated with 
tumor-load parameters, such as the degree of BMPC 
infiltration as assessed by histology (P<0.0001) and 
International Staging System (ISS) stage 3 (P=0.0001) 
(Figure 1). Apparently, it also indicated hematopoietic 
insufficiency, since patients without spleen signal had 
lower counts for hemoglobin (P<0.0001) and platelets 
(P<0.0001). In contrast, it was not significantly 
associated with age, gender, or the tumor progression 
markers gain(1q) and del(17p). In patients with 
lambda light chain MM, we observed a weak 
association between absence of spleen signal and 
increased serum free lambda light chain levels 
(P=0.03). Yet, adjusting for tumor load using the ISS 
stage as surrogate, there was no significant 
association. For kappa light chains, we did not see an 
association. The same holds true for the distribution 
of kappa and lambda light chain MM between 
patients with and without spleen signal. Using global 
gene expression data, we found no differentially 
expressed genes in MM cells between the two groups 
of patients. Together, our observations suggest that 
the absence of spleen signal is mainly associated with 
parameters reflecting tumor burden or hematopoietic 




Figure 1. Association between spleen signal on DW-MRI, tumor load, and hematopoietic insufficiency. In A representative inverted greyscale b800 DW-MRI 
images for progressing stages of plasma cell disorders are shown. While the individual with monoclonal gammopathy of undetermined significance (MGUS) presents with a 
hyperintense spleen, the spleen signal gradually decreases and is absent in the multiple myeloma (MM) patient with International Staging System (ISS) 3. B shows the proportion 
of patients without spleen signal within progressing stages of the disease. In C the association between spleen signal and laboratory parameters is depicted. BM: bone marrow; 
**** P< 0.0001 






Figure 2. The spleen signal during therapy. A Baseline and follow-up inverted greyscale b800 DW-MRI images and EADC maps are shown for one patient who initially 
presented w/o spleen signal but experienced re-appearance of the signal during therapy. B Loss of spleen signal during the course of the disease. The patient relapsed with 
multiple small focal lesions. Subsequently, the patient experienced progressive disease (PD) and developed a severe diffuse background pattern with concomitant loss of the 
spleen signal. 
 
The spleen signal is present in MGUS and 
reappears in MM patients during treatment 
To further address the association between the 
spleen signal and tumor load we hypothesized that 
individuals with MGUS should consistently present 
with preserved spleen signals due to the low level of 
PC infiltration in this condition. Therefore, we 
investigated 72 individuals with MGUS for whom 
DW-MRI data were available at our center. Indeed, in 
all MGUS cases the spleen signal was present. In 
addition, we monitored the spleen longitudinally in 
MM patients with absence of signal at diagnosis. The 
majority of these patients showed re-appearance of 
the spleen on DW-MRI as the tumor burden declined 
during treatment (follow-up scans available for 69 
patients, of those re-appearance in 57 (83%), example 
shown in Figure 2A). In these patients the mean 
hemoglobin level increased from 9.2 to 11.3 g/dl 
(baseline vs. time point of re-appearance; P<0.0001). 
Yet, the time point of re-appearance varied between 
patients. For 67 patients DW-MRI data was available 
within 3 months after the first ASCT, and we observed 





re-appearance of the spleen signal in 27 (40%). These 
27 patients showed deeper responses according to 
IMWG than patients without (≥ very good partial 
remission 85% vs. 45%, P=0.002). We also observed a 
trend for improved outcome in these patients (median 
PFS: 2.4 years vs. 5.5 years, P=0.07, median OS: not 
reached vs 5.8 years, P=0.07). 
Vice versa, we also observed loss of spleen signal 
during the course of treatment. Figure 2B shows a 
series of DW-MRI images for a patient who initially 
presented with multiple focal lesions and a clear 
spleen signal. At relapse from CR, multiple small focal 
lesions were detectable. Subsequently, the patient 
developed a severe diffuse background pattern with 
concomitant loss of the spleen signal, which is in line 
with high tumor burden diminishing the spleen 
signal. Of note, the diffuse BM signals at progressive 
disease and at the prior CR were similar, illustrating 
that intensity of the diffuse signal was not a good 
proxy for tumor infiltration during treatment. In 
contrast, in this patient the spleen signal was useful to 
discriminate between malignant and non-malignant/ 
reactive BM hyperintensities. 
Absence of spleen signal in high risk patients 
heralds dismal outcome  
To further investigate the prognostic value of the 
spleen signal we performed a survival analysis using 
loss of the spleen signal as categorical variable. 
Patients with absence of spleen signal at baseline 
experienced unfavorable outcome (hazard ratio of 1.8 
and p<0.05 for PFS and OS) in univariate analysis. 
Accounting for ISS, absence of spleen signal only 
showed a trend towards poor PFS (p=0.06), 
suggesting that the negative impact in the univariate 
analysis was due to the strong association between the 
spleen signal and tumor load. Yet, we observed an 
interaction between the GEP70 risk status and the 
spleen signal. While absence of spleen had no 
significant impact in GEP70 low risk patients, it 
defined a subgroup of GEP70 high risk patients with 
dismal outcome (median PFS: 0.97 years, HR: 2.96, 
Figure 3). The interaction term remained significant in 
a multivariate analysis including ISS, showing that 
the spleen signal can provide prognostic information 
independent from ISS in GEP high risk patients. 
Furthermore, dismal outcome could also be seen in 
patients without a spleen signal and presence of at 
least one of the high risk chromosomal aberrations 
t(4;14), t(14;16), gain(1q) or del(17p) (Figure 3). 
The asplenia phenomenon and extramedullary 
hematopoiesis  
Biopsying the spleen is risky and barely possible, 
and as a result it is difficult to directly investigate the 
pathological features of the spleen in patients with 
absence of the signal. Yet, as recently shown, a 
combination of modalities could improve our 
understanding of the biology underlying imaging 
phenomena [11]. A late stage relapsed patient with 
high tumor burden (>80%BMPC), a ferritin value of 
292 µg/l (reference 30-400 µg/l), and absence of 
spleen signal on DW-MRI also underwent Tc-99m 
labelled anti-CD66 antibody scintigraphy for 
evaluation of a targeted radiotherapy approach. The 
scintigraphy revealed extensive CD66 expression in 
the spleen (Figure 4). CD66 is expressed on mature 
myeloid cells including promyelocytes and 
granulocytes [14], and was recently used as a marker 
for extramedullary hematopoiesis (EMH) in a patient 
with myelofibrosis [15]. Thus, our preliminary 
observation suggests that EMH in the spleen is a 
factor that modifies the DW-MRI signal of this organ.  
Discussion 
In this study, we show for the first time that the 
restriction level of the spleen, an organ which is 
frequently overlooked during myeloma examinations, 
is a promising proxy for tumor load in MM and also 
associates with response and prognosis in newly 
diagnosed patients. While this is an unexpected 
finding, we appreciate that there are better methods 
and parameters for assessment of tumor load, risk 
prediction and therapy response. Yet, we see some 
clinical use for the spleen signal, further increasing the 
value of DW-MRI as a diagnostic tool in MM [9, 11, 
16-18]. First, despite its strong association with the 
ISS, absence of spleen signal has independent 
prognostic value: patients with high risk disease 
according to a GEP signature or FISH markers 
suffered from dismal outcome when the spleen was 
not detectable. Thus, as we move forward in 
integrating molecular data and functional imaging in 
the routine work up of patients with MM, we report 
on a clinically relevant finding which allows for 
identification of a subgroup with a particularly poor 
outcome. Secondly, our longitudinal data illustrates 
that the spleen signal could be used to improve 
discrimination between malignant and reactive 
DW-MRI hyperintensities. We performed a 
qualitative analysis (spleen signal present: yes/no) 
since our scan protocol had been optimized for 
reproduction of FLs. Yet, as shown in Figure 1, the 
intensity of the spleen gradually decreased from 
MGUS through the ISS stages. Therefore, we postulate 
that the relationship between spleen signal and tumor 
burden could even be better described with ADC 
values determined using more sophisticated scan 
protocols. 






Figure 3. Prognostic value of the spleen signal at baseline. Outcome of 295 NDMM patients enrolled into Total Therapy trials stratified by the spleen signal and (A) the 
GEP70 risk score or (B) risk according to FISH markers. FISH high risk was defined as presence of at least one of the following parameters: t (4;14), t(14;16), del(17p), or gain(1q). 
The log-rank test was used to perform the group comparison. 
 
Figure 4. The asplenia phenomenon and extramedullary hematopoiesis. A patient with advanced MM and absence of spleen signal on DW-MRI also underwent 
Tc-99m labelled anti-CD66 antibody scintigraphy. In (A) the b800 DWI and ADC maps are shown. In (B) results of the Tc-99m labelled anti-CD66 antibody scintigraphy are 
depicted. 
 
While our observations strongly support the 
hypothesis, that the spleen signal is associated with a 
high BMPC involvement, the biological mechanism 
for this phenomenon remains largely elusive as it 
would require spleen biopsies. Yet, using anti-CD66 
antibody scintigraphy in one patient with absence of 
spleen signal on DW-MRI, we observed a strong 
CD66 signal in the spleen, suggesting EMH to 
underlie the asplenia phenomenon in this patient. In 
principle, presence of EMH in patients with an 
obliterative BMPC involvement is not an unexpected 
finding, as MM cells crowd out other hematopoietic 





cells in the BM. In line, EMH in NDMM has 
previously been described by Seo et al., who 
performed a biopsy of a paravertebral mass with mild 
FDG uptake and detected EMH in this mass [19]. 
EMH in MM patients was also reported by Baldane et 
al. [20] and Palma JA et al. [21].  
Interestingly, Sato and colleagues observed 
hematopoietic cells solely in a tiny gap between the 
capsule and the amyloid protein-deposited spleen in a 
case of MM complicated by amyloid light chain (AL) 
amyloidosis with a traumatic splenic rupture after 
autologous stem cell transplantation [22]. In this 
context, infiltration of the spleen with amyloid 
proteins, primarily throughout the red pulp, has been 
identified in up to 41% of cases of systemic 
amyloidosis [22]. Since AL amyloidosis can present 
with diffuse low T2 MRI signal of the spleen [23], the 
DW-MRI signal of the spleen could also be altered in 
these patients. Although none of our NDMM patients 
was diagnosed with concomitant AL amyloidosis, we 
cannot rule out that light chain deposition impacted 
the spleen signal in our study. It is also conceivable 
that MM PCs directly modified the spleen signal by 
infiltrating this organ: a study by Oshima et al. 
showed that up to 30% of autopsied MM patients 
presented with splenic involvement [24]. Finally yet 
importantly, the magnetic susceptibility effect 
resulting from iron overload in the spleen due to red 
blood cell (RBC) transfusions is another factor that 
potentially modified DW-MRI findings in our study. 
However, from our clinical experience, extensive RBC 
transfusions in NDMM patients are uncommon.  
Conclusions 
We have observed an intriguing imaging 
phenomenon which is strongly associated with high 
tumor burden and hematopoietic insufficiency, and 
provides prognostic information in MM. Our 
preliminary investigations suggest EMH in the spleen 
to impact the DW-MRI signal but this needs to be 
confirmed in future studies.  
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